Table 1.
Patient demographics and baseline disease characteristics (N = 27 patients).
| Variable | No. of patients (%) |
|---|---|
| Age, years; median (range) | 53 (40–87) |
| Cutaneous primary | 23 (85) |
| Mucosal primary | 3 (11) |
| Unknown primary | 1 (4) |
| Gender | |
| Female | 9 (33) |
| Male | 18 (67) |
| Performance status (ECOG) | |
| 0 | 19 (70) |
| 1 | 8 (30) |
| Recurrent disease after prior surgery | 21 (78) |
| Prior adjuvant HDI | 10 (37) |
| Presence of in-transit metastases | 15 (55) |
| Estimated risk stage | |
| IIIB | 3 (11) |
| IIIC | 24 (89) |
| Tumor mutational status | |
| BRAFV600 | 9 (33) |
| NRASQ61 | 7 (26) |
| NRAS R73 | 1 (4) |
| Unknown | 3 (11) |
HDI: high dose interferon-α; ECOG: Eastern Cooperative Oncology Group.